Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
1997-2-12
pubmed:abstractText
This study evaluated the pharmacological and behavioral effects of S 21,357, a drug with high affinity for both 5-HT1A and 5-HT2A receptors. The drug behaved as antagonist at both 5-HT1A autoreceptors and postsynaptic 5-HT1A receptors, as it prevented the inhibitory effect of lesopitron on the electrical discharge of the dorsal raphé nucleus (DRN) 5-HT neurons and the activity of forskolin-stimulated adenylate cyclase in hippocampal homogenates. In addition, S 21,357 (4 and 128 mg/kg, PO) inhibited 5-HTP-induced head-twitch responses in mice, indicating that it possesses 5-HT2A antagonistic properties. In a test battery designed to assess defensive behaviors of Swiss-Webster mice to the presence of, or situations associated with, a natural threat stimulus (i.e., rat), S 21,357 (0.12-2 mg/kg, IP) reduced contextual defense reactions after the rat was removed, risk assessment activities when the subject was chased, and finally, defensive attack behavior. These behavioral changes are consistent with fear/anxiety reduction. Furthermore, the drug strongly reduced flight reactions in response to the approaching rat. This last finding, taken together with recent results with panic-modulating drugs, suggest that S 21,357 may have potential efficacy against panic attack. Finally, our results suggest that compounds sharing high affinities for both 5-HT1A and 5-HT2A receptors may directly or synergistically increase the range of defensive behaviors affected.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0091-3057
pubmed:author
pubmed:issnType
Print
pubmed:volume
54
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
509-16
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:8743616-Adenylate Cyclase, pubmed-meshheading:8743616-Animals, pubmed-meshheading:8743616-Anti-Anxiety Agents, pubmed-meshheading:8743616-Avoidance Learning, pubmed-meshheading:8743616-Behavior, Animal, pubmed-meshheading:8743616-Benzothiazoles, pubmed-meshheading:8743616-Brain Chemistry, pubmed-meshheading:8743616-Dose-Response Relationship, Drug, pubmed-meshheading:8743616-Electrophysiology, pubmed-meshheading:8743616-Male, pubmed-meshheading:8743616-Mice, pubmed-meshheading:8743616-Motor Activity, pubmed-meshheading:8743616-Piperidines, pubmed-meshheading:8743616-Raphe Nuclei, pubmed-meshheading:8743616-Rats, pubmed-meshheading:8743616-Rats, Sprague-Dawley, pubmed-meshheading:8743616-Receptors, Serotonin, pubmed-meshheading:8743616-Serotonin Antagonists, pubmed-meshheading:8743616-Synaptic Transmission, pubmed-meshheading:8743616-Thiazoles
pubmed:year
1996
pubmed:articleTitle
Preclinical profile of the mixed 5-HT1A/5-HT2A receptor antagonist S 21,357.
pubmed:affiliation
Békésy Laboratory of Neurobiology, John A. Burns School of Medicine, University of Hawaii, Honolulu 96822, USA.
pubmed:publicationType
Journal Article, In Vitro